JP2008110942A - Antioxidant composition containing astaxanthin, zinc and selenium - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an antioxidant, a liver function improver, a lactic acid-accumulation inhibitor, a muscle damage improver and a muscle improver, and to provide a food and drink having antioxidant effects, liver function-improving effects, lactic acid accumulation-inhibiting effects, muscle damage-improving effects and muscle-improving effects. <P>SOLUTION: The composition containing astaxanthin, zinc and selenium is found to have the antioxidant effects, the liver function-improving effects, the lactic acid accumulation-inhibiting effects, the muscle damage-improving effects and the muscle-improving effects higher than those by each single use. The medicine and the food and drink having these effects contain them. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

  The present invention relates to a composition comprising astaxanthin, zinc and selenium, and further to an antioxidant, a liver function improving agent, a lactic acid accumulation inhibitor, a muscle damage improving agent and a muscle improving agent. In addition, the present invention relates to foods and drinks containing antioxidants, liver function improving agents, lactic acid accumulation inhibitors, muscle damage improving agents, and muscle improving agents.

  Astaxanthin is a kind of carotenoid, widely distributed in nature, such as crustaceans such as shrimp and crab, fish such as salmon and Thailand, algae such as green alga Hematococcus, yeasts such as red yeast Phaffia, etc. It is used. Astaxanthin is known to have an in vivo anti-acid effect (Patent Document 1), an liver function improving effect (Patent Document 2), and an effect of improving muscle damage and disease (Patent Document 3). It has been.

  Zinc is an essential metal element next to iron in the body, and is contained in about 1 to 3 g in the human body, and is involved in structure formation and maintenance in many enzymes. In particular, it works as a component of antioxidant enzymes (such as SOD). In particular, it works to repair and improve damaged or damaged organs. Due to zinc deficiency, abnormal reproductive function and immune function, sensory organ (sight, taste, olfactory) disorder, skin disorder, metabolic dysfunction, loss of appetite, growth disorder, etc. are known. It is known that excessive intake of zinc results in a deficiency of iron and copper and a decrease in the blood concentration of good high density lipoprotein.

  Selenium is contained in the human body in an amount of about 2 to 20 mg. In vivo, it is mainly incorporated into a protein as selenocysteine and works as a selenoprotein, and is involved in antioxidants such as glutathione peroxidase, thioredoxin reductase, SOD, etc. Is a component of In addition, it cooperates with antioxidants such as vitamin E and vitamin C to protect the living body from active oxygen and radicals. Due to selenium deficiency, anemia, hypertension, sperm reduction, cancer (particularly prostate cancer), arthritis, premature aging, muscle atrophy, and multiple sclerosis are known. Nausea, nausea, diarrhea, loss of appetite, headache, immunosuppression, decreased high-density lipoprotein, etc. are known due to excessive intake of selenium.

  In the living body, active oxygen is generated, causing various obstacles. In particular, a large amount of active oxygen is generated in organs such as muscles and livers that are actively active, causing damage and damage to the organs. Under normal conditions, enzymes such as SOD (superoxide dismutase) and GPX (glutathione peroxidase) work to remove active oxygen, but alcohol, drugs, overwork, viruses, stress, and excessive exercise can reduce active oxygen. It can no longer be removed, causing damage and damage to the organ.

Until now, astaxanthin, zinc and selenium have been known for their antioxidative effects, liver function improving effects, and muscle damage improving effects in vivo. It is not known to have liver function improving effect, lactic acid accumulation inhibiting effect, muscle damage improving effect and muscle improving effect. So far, zinc and selenium have been administered individually or as minerals at the same time, but their nutritional effects have not been expected, and there are concerns about side effects of overdose of zinc and selenium. Effective in reducing the side effects of selenium.
Japanese Unexamined Patent Publication No. 2-49091 Japanese Unexamined Patent Publication No. 9-124470 Japan Special Table 2001-514215

  As a result of searching for an antioxidant composition to solve the above problems, the present inventors have found that a composition containing astaxanthin, zinc and selenium has a more antioxidant effect. The present invention has been completed based on such findings, and provides an antioxidant and liver function improving agent, a lactate accumulation inhibitor, a muscle damage improving agent and a muscle improving agent containing astaxanthin, zinc and selenium. is there.

  The object of the present invention is to provide means for solving such problems.

  As a result of diligent research to solve the above problems, the present inventors have found that a composition containing astaxanthin, zinc and selenium has an antioxidant effect and a liver function improving agent, a lactic acid accumulation inhibitor, a muscle damage improving agent and a muscle improving agent. It was found to show. The present invention is based on such knowledge.

That is, the present invention is a composition comprising (1) the following components (A) and (B); (A) one or more of astaxanthin, (B) zinc and selenium,
(2) The composition of (1) contains (C) one or more of allicin, allinin, curcuminoid, capsaicin, polyphenol, carotenoid, flavonoid, coenzyme Q10, α-lipoic acid, carnitine, anserine, and carnosine. And a composition
(3) An antioxidant comprising the composition of (1) to (2),
(4) A liver function improving agent comprising the composition of (1) to (2),
(5) A lactic acid accumulation inhibitor comprising the composition of (1) to (2),
(6) A muscle damage-improving agent comprising the composition of (1) to (2),
(7) A muscle enhancer comprising the composition of (1) to (2),
(8) A food or drink containing the medicine according to claims 3 to 7.

  In the present invention, astaxanthin means a product derived from a natural product or obtained by synthesis. Examples of those derived from natural products include crustacean shells such as shrimp, krill and crabs, eggs and organs, various seafood skins and eggs, algae such as the green alga Hematococcus, yeasts such as red yeast Phaffia, Examples thereof include those obtained from seed plants such as marine bacteria, Fukujukusa, and Golden phoenix flowers. Natural extracts and chemically synthesized products are commercially available and are readily available.

  Astaxanthin is 3,3′-dihydroxy-β, β-carotene-4,4′-dione and has stereoisomers. Specifically, three stereoisomers of (3R, 3′R) -astaxanthin, (3R, 3 ′S) -astaxanthin and (3S, 3 ′S) -astaxanthin are known. Any of these can be used.

  Astaxanthin is known not to be mutagenic and is a highly safe compound, and is widely used as a food additive (Jiro Takahashi et al .: Toxicity test of hematococcus alga astaxanthin-Ames test, rat Single-dose toxicity test, rat 90-day repeated oral dose toxicity test, clinical medicine, 20: 867-881, 2004).

  In the present invention, astaxanthin includes free forms, monoester forms and diesters of astaxanthin.

  As the drug containing astaxanthin of the present invention as an active ingredient, at least one of astaxanthin free form, monoester form and diester form can be used. Diesters are physically more stable than free and monoesters because the two hydroxyl groups are protected by ester bonds, and are less susceptible to oxidative degradation in the composition. However, it is considered that when it is taken into the living body, it is rapidly hydrolyzed to free astaxanthin by an in vivo enzyme and exhibits an effect.

  Examples of astaxanthin monoesters include esters esterified with lower or higher saturated fatty acids or lower or higher unsaturated fatty acids. Specific examples of the lower or higher saturated fatty acid or the lower or higher unsaturated fatty acid include acetic acid, lauric acid, myristic acid, pentadecanoic acid, palmitic acid, palmitooleic acid, hebutadecanoic acid, elaidic acid, ricinoleic acid, and betrothelin. Acid, vaccenic acid, eleostearic acid, punicic acid, ricinic acid, parinaric acid, gadoric acid, 5-eicosenoic acid, 5-docosenoic acid, cetoleic acid, erucic acid, 5,13-docosadienoic acid, ceracholic acid, decenoic acid , Stering acid, dodecenoic acid, oleic acid, stearic acid, eicosaopentaenoic acid, docosahexaenoic acid, linoleic acid, linolenic acid, arachidonic acid and the like. Examples of the diester of astaxanthin include diesters esterified with the same or different fatty acids selected from the group consisting of the above fatty acids.

  Furthermore, astaxanthin monoesters include amino acids such as glycine and alanine; mono- or polyvalent carboxylic acids such as acetic acid and citric acid; inorganic acids such as phosphoric acid and sulfuric acid; sugars such as glucoside; glycerosugar fatty acids and sphingosaccharides. Examples thereof include sugar esters such as fatty acids; fatty acids such as glycero fatty acids; monoesters esterified with glycerophosphoric acid and the like. In addition, the salt of the said monoester is also included when it can be considered.

  Astaxanthin diester is a group consisting of the lower saturated fatty acid, higher saturated fatty acid, lower unsaturated fatty acid, higher unsaturated fatty acid, amino acid, mono- or polyvalent carboxylic acid, inorganic acid, sugar, sugar fatty acid, fatty acid and glycerophosphoric acid And diesters esterified with the same or different acids selected from In addition, the salt of the said diester is also included when it can be considered. Examples of the diester of glycerophosphoric acid include saturated fatty acid esters of glycerophosphoric acid or glycerophosphoric acid esters containing fatty acids selected from higher unsaturated fatty acids, unsaturated fatty acids or saturated fatty acids.

  In the present invention, astaxanthin can be derived from a natural product or obtained by synthesis, but is preferably derived from a natural product in which an astaxanthin ester is dissolved in various oils and fats from absorption in the body. Natural sources include, for example, a krill extract, a faffia yeast extract, and a hematococcus alga extract. Particularly preferred is a hematococcus alga extract depending on the stability of astaxanthin and the type of ester of astaxanthin. Among them, “Asterel” (trademark, manufactured by Fuji Chemical Industry Co., Ltd.) is most preferable because of its good stability and absorbability.

Haematococcus algae is a green algae belonging to the family Volvox Chlamydomonas. Usually, since it is a green alga, it has a high chlorophyll content and is green, and it swims in water with two flagella. However, under starvation conditions such as nutrient deficiency and temperature changes, dormant spores are formed, the astaxanthin content becomes high, and red spheres are formed. In the present invention, hematococcus in any state can be used, but it is preferable to use hematococcus that has become dormant spores containing a large amount of astaxanthin. In addition, among green algae belonging to the genus Haematococcus, for example, Haematococcus pluviaris is preferable.

  As a method for culturing Haematococcus green algae, a hermetically sealed culture method is preferred in which no foreign microorganisms are mixed and propagated and other contaminants are not mixed. For example, a partially open-type dome shape, conical shape or cylindrical shape is preferable. A culture method using a culture medium having a culture apparatus and a gas discharge device movable within the apparatus (International Publication No. 99/50384), or culturing by irradiating light from inside a sealed culture apparatus And a method using a flat culture tank or a tube-type culture layer are suitable.

  As a method for obtaining an extract from Haematococcus algae according to the present invention, (1) a method of drying and crushing Haematococcus, then performing supercritical extraction using carbon dioxide as an extraction solvent, and removing the carbon dioxide to obtain an extract (2) After suspending Haematococcus (wet powder) in an organic solvent, the cells are pulverized and extracted through a pulverizer, and the organic solvent is removed to obtain an extract.

  The extraction method by supercritical extraction can be performed by a conventional method, for example, the method of Hirose et al. (Ind Eng Chem Res, 2006, 45 (10), 3652-3657, Extraction of Astaxanthin from Haematococcus pluvialis Using Supercritical CO2 and Ethanol as Entrainer).

  Various methods for extracting with an organic solvent are known. For example, since astaxanthin and its esters are oil-soluble substances, astaxanthin-containing components can be extracted from natural products containing astaxanthin with an oil-soluble organic solvent such as acetone, alcohol, ethyl acetate, benzene, and chloroform. Also, supercritical extraction can be performed using carbon dioxide, water, or the like. After extraction, the solvent is removed according to a conventional method to obtain a mixed concentrate of monoester type astaxanthin and diester type astaxanthin. The obtained concentrate can be further purified by separation column or lipase decomposition, if desired.

  A method of drying Haematococcus algae cultured in the above-mentioned dome type culture apparatus or closed type culture apparatus, extracting with acetone after pulverization, or performing pulverization and extraction in acetone at the same time, and then removing acetone to extract astaxanthin (Japanese Patent Laid-Open No. 2006-70114) has almost no oxidation of astaxanthin because it does not come into contact with air, and there are few impurities, that is, there are few substances that inhibit the effect of the present invention, and it contains astaxanthin and triglycerides in high purity. This is preferable.

  Astaxanthin is used in the form of astaxanthin extract obtained by the above-mentioned method and powder or aqueous solution containing them, or dried products such as red yeast Phaffia, green algae hematococcus, marine bacteria, and crushed products thereof. it can.

  Zinc and selenium used in the composition of the present invention can be blended in the form of the compound as it is or in the form in which the compound is eaten by the organism. The compound may be either an inorganic salt or an organic salt. Examples of the inorganic salt include sulfate, hydrochloride, nitrate, hydrotalcite, and oxide. Examples of the organic salt include acetic acid, succinic acid, gluconic acid, and ascorbic acid. It can mix | blend with salts, such as. Examples of organisms that feed on zinc salts and selenium salts include bacteria, microalgae, and yeast. From the viewpoint of good absorbability and elution, a yeast fed with zinc salt and selenium salt, an inorganic substance dissolved in hydrotalcite, and a gluconate are preferred.

  The amount of astaxanthin used in the composition of the present invention is an astaxanthin free form equivalent amount, and is administered orally or parenterally at a dose of 0.5 to 100 mg, preferably 1 to 20 mg per day for an adult. The dosage varies depending on the age, weight, symptom level, and dosage form of the patient to be administered. The amount of astaxanthin in the pharmaceutical product of the present invention can be contained in an amount of 0.01 to 99.9% by weight, preferably 0.1 to 90% by weight.

  The amount of zinc used in the composition of the present invention is 1 to 100 mg, preferably 3 to 30 mg per day for adults in terms of zinc alone, and is administered orally or parenterally. The dosage varies depending on the age, weight, sex, degree of symptoms, and dosage form of the patient to be administered. The amount of zinc in the pharmaceutical product of the present invention can be contained in an amount of 0.01 to 99.9% by weight, preferably 0.1 to 90% by weight.

  The amount of selenium used in the composition of the present invention is 1 to 900 μg, preferably 7 to 450 μg per day for adults in terms of selenium alone, orally or parenterally. The dosage varies depending on the age, weight, sex, degree of symptoms, and dosage form of the patient to be administered. The amount of selenium in the pharmaceutical product of the present invention can be contained in an amount of 0.001 to 10% by weight, preferably 0.01 to 5% by weight.

  In the composition of the present invention, astaxanthin, zinc and selenium can be blended in a ratio of astaxanthin: zinc: selenium = 100: 0.1 to 10000: 0.001 to 90, respectively, preferably astaxanthin: zinc. : Selenium = 100: 0.3 to 3000: 0.007 to 45.

  Examples of other beneficial ingredients used in the present invention include one or more of allicin, alliin, curcuminoid, capsaicin, tocotrienol, polyphenol, carotenoid, flavonoid, coenzyme Q10, α-lipoic acid, carnitine, anserine, and carnosine. In particular, allicin, alliin, inodo, and capsaicin are preferable. These can be derived from natural sources and synthetic products, and natural products containing them can be used. These components are generally blended in an amount of 0.01 to 90%, preferably 0.1 to 10%, and can be used in combination of one or more.

  In the present invention, tocotrienol includes isomers and derivatives of tocotrienol, isomers and derivatives of tocopherol, and those derived from natural products or obtained by synthesis, for example, α-tocotrienol, β-tocotrienol, γ- It means tocotrienol, δ-tocotrienol, tocotrienol nicotinate of each of these isomers, and the like. These tocotrienols include d-, l- and dl-type isomers. Moreover, it can be used also as a 1 type or more, or 2 or more types of mixture. These tocotrienols can be obtained by a conventional method, for example, by a method such as compression of a natural product, extraction from a natural product, or synthesis. These tocotrienols may be further purified by separation and purification, for example, by column chromatography or the like, if desired.

  The composition of the present invention has a good antioxidant effect in vivo and on the skin surface, and is particularly used as a drug having a liver function improving effect, a lactic acid accumulation inhibiting effect, a muscle damage improving effect, a muscle improving effect, and a food and drink. Can do. The composition of the present invention can be used as an antioxidant, a liver function improving agent, a lactic acid accumulation inhibitor, a muscle damage improving agent, and a muscle improving agent. It has the effect of inhibiting the accumulation of lactic acid generated during exercise, improving muscle damage, and improving the production and growth of the muscle itself, so it is effective in improving exercise ability, especially the exercise ability that requires endurance. In addition, the muscles themselves can be improved by improving the amount of exercise exercise and thereby restoring the damaged muscles. Furthermore, a heavy exercise such as long-term exercise produces waste products such as lactic acid, which can improve liver function caused by decomposing them.

  In the present invention, the composition containing astaxanthin, zinc and selenium shows a remarkable effect than each of them alone, although the detailed cause is unknown. 1) Astaxanthin suppresses lipid peroxidation. 2) Zinc and selenium acted as a prosthetic factor for active oxygen scavenging enzymes such as superoxide dismutase and glutathione peroxidase, and promoted the activities of superoxide dismutase and glutathione peroxidase. .

  The agent of the present invention can be administered orally or parenterally. Oral dosage forms are administered in solid dosage forms such as tablets, buccal disintegrating tablets, capsules, granules, fine granules, and liquid dosage forms such as syrups and suspensions. Parenteral dosage forms are administered in the form of nasal drops, patches, ointments and suppositories.

  The agent of the present invention may contain an appropriate amount of various additives used for the production of general preparations. Examples of such additives include excipients, binders, acidulants, foaming agents, artificial sweeteners, fragrances, lubricants, colorants, stabilizers, pH adjusters, and surfactants. Examples of excipients include corn starch, potato starch, wheat starch, rice starch, partially pregelatinized starch, pregelatinized starch, and starches such as porous starch, sugars such as lactose, sucrose, and glucose, mannitol, xylitol, Examples thereof include sugar alcohols such as erythritol, sorbitol, maltitol, magnesium aluminate metasilicate, hydrotalcite, anhydrous calcium phosphate, precipitated calcium carbonate, calcium silicate, and light anhydrous silicic acid. Examples of the binder include hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, gum arabic powder, gelatin, and pullulan. Examples of the disintegrant include starch, agar, carmellose calcium, sodium carboxymethyl starch, croscarmellose sodium, crospovidone, crystalline cellulose, and F-MELT (trademark, manufactured by Fuji Chemical Industry Co., Ltd.). Examples of sour agents include citric acid, tartaric acid, malic acid, ascorbic acid and the like. Examples of the foaming agent include sodium bicarbonate and sodium carbonate. Examples of the sweetener include saccharin sodium, dipotassium glycyrrhizin, aspartame, stevia and thaumatin. Examples of the fragrances include lemon oil, orange oil, menthol and the like. Examples of the lubricant include magnesium stearate, sucrose fatty acid ester, polyethylene glycol, talc, stearic acid, and sodium stearyl fumarate. Examples of the colorant include edible pigments such as edible yellow No. 5, edible red No. 2, and edible blue No. 2, edible lake pigments, and iron sesquioxide. Examples of the stabilizer include sodium edetate, tocopherol, cyclodextrin and the like. Examples of the pH adjuster include citrate, phosphate, carbonate, tartrate, fumarate, acetate, amino acid salt and the like. Examples of the surfactant include polysorbate 80, methyl cellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, polyoxyethylene sorbitan monolaurate, gum arabic, and powdered tragacanth. In order to improve the absorption and formulation of astaxanthin and tocotrienol, it is preferable to blend in powder form.

  In order to assist the medicinal effect of the present invention, a substance having an assisting effect can be added. For example, nucleic acid-related substances such as deoxyribonucleic acid and salts thereof, adenylic acid derivatives such as adenosine triphosphate and adenosine monophosphate and salts thereof, ribonucleic acid and salts thereof, guanine, xanthine and derivatives thereof and salts thereof; Extracts derived from animals such as serum deproteinized extract, spleen extract, placenta extract, chicken crown extract, royal jelly; extract derived from microorganisms such as yeast extract, lactic acid bacteria extract, bifidobacteria extract, ganoderma extract Extracts from plants such as carrot extract, assembly extract, rosemary extract, buckwheat extract, garlic extract, hinokitiol, cephalanthin; α- or γ-linolenic acid, eicosapentaenoic acid and their derivatives, Succinic acid and its derivatives and their salts, estradiol and its derivatives and their Α-hydroxy acids such as glycolic acid, lactic acid, malic acid, citric acid, salicylic acid and their derivatives and their salts, glycyrrhizic acid, glycyrrhetinic acid, mefenamic acid, phenylbutazone, indomethacin, ibuprofen, ketoprofen, allantoin , Guaiazulene and derivatives thereof and salts thereof, ε-aminocaproic acid, zinc oxide, diclofenac sodium, hyaluronic acid, chondroitin, collagen, aloe extract, salvia extract, arnica extract, chamomile extract, birch extract, hypericum Extract, eucalyptus extract and mugwort extract, tyrosinase activity inhibitor, cysteine and its derivatives and salts thereof, Sempukuka extract, keiketto extract, sunpens extract, suhakuhihi extract, toki Extract, Ibukitorano extract, Clara extract, Hawthorn extract, Shirayuri extract, Hop extract, Neubara extract and Yokuinin extract, Hyaluronic acid, Chondroitin sulfate, Dermatan sulfate, Heparan sulfate, Heparin and Keratan sulfate and these Salt, collagen, elastin, keratin and derivatives thereof, and salts thereof, deep sea water, loofah extract, papaya extract, papaya powder, zinc, ginseng extract, bullberry extract, DHA, ginkgo biloba extract, glutathione Vitamins such as D, ascorbic acid and L-ascorbic acid; tocopherols, vitamin E acetate, vitamin E succinate, vitamin E phosphates Vitamin E such as Flavonoi , Tannic, ellagic acid, nucleic acids, Chinese medicines such, seaweeds, etc. inorganic, and may be selected one or more from the group consisting of mixtures thereof. Tocotrienol is preferred. Moreover, the same effect can be acquired also by mix | blending dry powder, such as the fruit containing these, leaf bud, algae, and fungi.

  Liquid preparations such as syrups, drinks, and suspensions contain active ingredients in the presence of pH adjusters, buffers, solubilizers, suspensions, etc., tonicity agents, stabilizers, preservatives, and the like as necessary. It can be formulated by a conventional method. Examples of the suspending agent include polysorbate 80, methyl cellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, polyoxyethylene sorbitan monolaurate, gum arabic, and powdered tragacanth. Examples of the solubilizer include polysorbate 80, hydrogenated polyoxyethylene castor oil, nicotinamide, polyoxyethylene sorbitan monolaurate, macrogol, and castor oil fatty acid ethyl ester. Examples of the stabilizer include sodium sulfite and sodium metasulfite. Examples of the preservative include methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, sorbic acid, phenol, cresol, chlorocresol and the like.

  In addition to the above components, the form of the external preparation for skin is usually used for external preparations for skin such as cosmetics and pharmaceuticals, for example, whitening agents, moisturizers, antioxidants, oily components, ultraviolet absorbers, surface active agents. Agents, thickeners, alcohols, powder components, colorants, aqueous components, water, various skin nutrients, and the like can be appropriately blended as necessary.

  The composition and medicine of the present invention can be used by blending with food and drink and feed, and the same effect can be obtained.

  As foods and drinks, supplements, functional health foods, special-purpose foods can be used as supplements, functional health foods, special-purpose foods, and general foods. And in solid dosage forms such as tablets, fast-disintegrating tablets, capsules, granules, fine granules, and liquid dosage forms such as syrups and suspensions. Among ingredients used in the above pharmaceutical preparations, those that can be used in foods can be selected, in addition to milk protein, soy protein, egg albumin protein, etc., or egg white oligopeptide, soy hydrolyzate that is a degradation product thereof, A mixture of amino acids alone can also be used in combination. In addition, when provided in the form of a drink, nutritional additives such as amino acids, vitamins and minerals, sweeteners, spices, flavors and pigments may be added to improve the nutritional balance and flavor during intake. Good. The form of the food or drink of the present invention is not limited to these.

  Examples of forms of general foods, that is, foods and drinks include margarine, butter, butter sauce, cheese, fresh cream, shortening, lard, ice cream, yogurt, dairy products, sauce meat products, fish products, pickles, french fries, potato chips , Snacks, kakimochi, popcorn, sprinkles, chewing gum, chocolate, pudding, jelly, gummy candy, candy, drop, caramel, bread, castella, cake, donuts, biscuits, cookies, crackers, macaroni, pasta, ramen, buckwheat, udon , Salad oil, instant soup, dressing, eggs, mayonnaise, miso, etc. or carbonated or non-carbonated beverages such as fruit juices, soft drinks, sports drinks, non-alcoholic beverages such as tea, coffee, cocoa It can be the addition example of liqueur, to common foods such as alcoholic beverages, such as medicinal liquor.

  In food and drink, astaxanthin, zinc and selenium are blended together with raw materials for general foods, and are manufactured by processing according to conventional methods. The amount of astaxanthin, zinc and selenium varies depending on the form of the food and is not particularly limited, but in general, the amount of astaxanthin, zinc and selenium used can be appropriately selected by those skilled in the art according to the type of food and drink. The amount can be blended.

  In order to describe the present invention in more detail, examples will be given below, but it goes without saying that the present invention is not limited to these examples.

Example 1 Action of Astaxanthin, Selenium and Zinc on Superoxide Anion Radical Confluent HepG2 cells were cultured in DMEM medium, and astaxanthin 10 ng / ml or selenomethionine (0.7 ng / ml as selenium) + zinc gluconate ( 15 ng / ml as zinc) or 10 ng / ml astaxanthin + selenomethionine (0.7 ng / ml as selenium) + zinc gluconate (15 ng / ml as zinc) and incubated for 24 hours, then the cells were collected and washed twice with PBS Washed. The washed cells are homogenized in cold PBS containing protease inhibitors, and superoxide anion radicals are generated by the xanthine-xanthine oxidase method according to the method of Tien et al. (In Lipid Peroxides in Biology and Medicine, p.23-39, 1982). TBARS, which is an index of lipid peroxidation, was quantified according to a conventional method, and the inhibition rate relative to the control was calculated.

[Table 1] Inhibition rate of lipid peroxidation

  From this result, it was observed that those administered with a combination of astaxanthin, selenium and zinc significantly inhibited the generation of superoxide anion radicals synergistically as compared with those administered with astaxanthin alone, selenium and zinc.

[Example 2] Effects of astaxanthin, selenium and zinc on oxidative tissue damage in vivo As shown in Table 2, rats were orally administered daily for 5 days to each group, and then the liver was removed and liver mitochondria were isolated. Washed with potassium chloride Tris-HCl buffer. Mitochondria with a protein amount of 2 mg / mL was added to a potassium chloride-Tris-HCl buffer, and divalent iron (Mole salt) was added to a concentration of 50 μM. Lipid peroxidation was performed at 37 ° C for 60 minutes. To this, 0.5 mL of 40% trichloroacetic acid, 0.25 mL of 5N hydrochloric acid and 0.5 mL of 2% thiobarbitouric acid aqueous solution were added, and the mixture was boiled at 100 ° C. for 15 minutes to carry out TBA reaction. The reaction mixture was centrifuged, and the supernatant was quantified for lipid peroxide at an absorbance of 535 nm, and the inhibitory action of each substance on the lipid peroxidation reaction was examined.

[Table 2] Inhibition rate of biological membrane lipid peroxidation in rat skeletal muscle and liver

  As a result, it was observed that combining astaxanthin, selenium and zinc synergistically inhibits lipid peroxidation in the living body as compared to astaxanthin alone.

[Production Example 1] Tablets The following ingredients were uniformly mixed at the following composition ratio (% by weight) to give a tablet of 300 mg per tablet.
Asteryl powder 10 parts by weight Zinc gluconate 1 part by weight Selenium-containing yeast 1 part by weight V premix 3 parts by weight Lactose 50 parts by weight Potato starch 32 parts by weight Polyvinyl alcohol 2 parts by weight Magnesium stearate 1 part by weight Asteryl powder (Fuji Chemical) Kogyo Co., Ltd.) is a powder produced from Haematococcus alga extract oil containing 1% by weight astaxanthin in terms of free form.

[Production Example 2] Soft capsule contents were kneaded into a soft capsule skin composed of the following components according to a conventional capsule method and filled to obtain 300 mg of soft capsules. In addition, in 1 grain, it is equivalent to 3 mg of astaxanthin, 3 mg of zinc, and 50 μg of selenium.
Soft capsule skin gelatin 70 parts by weight Glycerin 23 parts by weight Propyl paraoxybenzoate 0.5 part by weight Water 6.5 parts by weight Soft capsule content Asteryl 50F 60 parts by weight Zinc gluconate 21 parts by weight Selenium-containing yeast 0.5 part by weight Chain fatty acid triglyceride 20 parts by weight Corn starch 58.5 parts by weight Asterel 50F (manufactured by Fuji Chemical Industry Co., Ltd.) is an oil produced from an extract of Haematococcus alga containing 5% by weight of astaxanthin in terms of free form.

[Production Example 3] Orally rapidly disintegrating tablet The following components were uniformly mixed at the following composition ratio (% by weight) to give a tablet of 300 mg per tablet.
Asteryl powder 10 parts by weight Zinc gluconate 1 part by weight Selenium-containing yeast 1 part by weight V premix 3 parts by weight F-MELT 40 parts by weight Rice starch 24 parts by weight Magnesium stearate 1 part by weight

[Production Example 4] Biscuits The following ingredients were blended and biscuits were baked according to a conventional method.
Asteryl powder 10 parts by weight Zinc gluconate 1 part by weight Selenium-containing yeast 1 part by weight Milk 430 parts by weight Sugar 180 parts by weight Corn starch 280 parts by weight Salt 10 parts by weight

Claims (8)

Next components (A) and (B)
(A) Astaxanthin,
(B) one or more of zinc and selenium,
The composition characterized by containing. The composition according to claim 1, comprising (C) one or more of allicin, alliin, curcuminoid, capsaicin, polyphenol, carotenoid, flavonoid, coenzyme Q10, α-lipoic acid, carnitine, anserine, and carnosine. object. An antioxidant comprising the composition of claims 1-2. The liver function improving agent containing the composition of Claims 1-2. A lactic acid accumulation inhibitor comprising the composition according to claim 1. A muscle injury-improving agent comprising the composition according to claim 1. The muscle improvement agent containing the composition of Claims 1-2. A food or drink comprising the drug according to claim 3.